ISPE

JULY 7, 2023

USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics Trudy Patterson Fri, 07/07/2023 - 08:45 Features July / August 2023 USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics John F. This article summarizes trends from the workshop and ponders next steps. Biotechnology and Bioengineering (2023): 1–6.

FDA 52

FDA Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

OCTOBER 7, 2020

SMi Reports: An exclusive interview with María José López Barragán, Founder, Barragan BioConsulting, formerly CMC Product Quality Reviewer, FDA, who will be speaking at the 3rd Annual Pharmaceutical Microbiology East Coast Conference released. Workshop: October 30th, 2020. María José (Pepa) Lopez Barragán is a former U.S.

FDA 52

FDA Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

APRIL 13, 2023

Legislative hurdles aside, in the same way as any other pharmaceutical companies, psychedelics companies will need to obtain regulatory approvals in the countries where they will carry out clinical trials or market products. Additionally, several US and Canadian states have legalised or decriminalised magic mushrooms.

Pharmaceutical Companies 131

Pharmaceutical Companies Pharmaceutical Companies FDA 131

ISPE

NOVEMBER 1, 2022

The first keynote speaker was Michael Kopcha, PhD, RPh, Director of the Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), US FDA. He presented on “Quality: A Key Ingredient for Stable Pharmaceutical Supply Chains.”. Director, Office of Pharmaceutical Quality. Tue, 11/01/2022 - 06:49.

FDA 98

FDA Insurance Chemotherapy Documentation 98

ISPE

MAY 9, 2023

Surrounded by universities and community colleges with life sciences programs, companies in RTP were able to access highly skilled graduates, increasing employment in the state. By the 1990s, pharmaceutical companies were looking to partner with contract research organizations (CROs) for drug development and clinical trials.

Vaccines 94

Vaccines Pharmaceutical Companies Pharmaceutical Companies Medical Schools 94

ISPE

JULY 5, 2023

For example, one pharmaceutical company that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. 5 In addition, there are human elements to consider.

FDA 52

FDA Dosage Documentation Pharmaceutical Companies 52